1. Koran LM. Medical conditions associated with obsessive compulsive symptoms. In LM Koran, Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide. New York: Cambridge University Press, 1999;81.

2. Ratey JJ, Dymek MP. Neuropsychiatry of mental retardation and cerebral palsy. In BS Fogel, RB Schiffer, SM Rao (eds), Neuropsychiatry. Baltimore: Williams & Wilkins, 1996;549–571.

3. Borthwick-Duffy SA. Epidemiology and prevalence of psychopathology in people with mental retardation. J Consult Clin Psychol 1994;62(1):17–27.

4. Duffy JD. The management of patients with developmental disabilities. Advances in Neuropsychiatry course. Presented at the one hundred fifty-first annual meeting of the American Psychiatric Association. Toronto, Ontario, Canada, May 30–June 4, 1998.

5. Lovell RW, Reiss AL. Dual diagnosis: psychiatric disorders in developmental disabilities. Pediatr Clin North Am 1993;40(3):579–592.

6. Meins W. Symptoms of major depression in the mentally retarded adults. J Intellect Disabil Res 1995;39:41–45.

7. King BH, DeAntonio C, McCracken JT, et al. Psychiatric consultation in severe and profound mental retardation. Am J Psychiatry 1994;151(12):1802–1808.

8. Schmitz B, Trimble M. Epileptic equivalents in psychiatry: some nineteenth century views. Acta Neurol Scand Suppl 1992;140:122–126.

9. Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis 1986;174:471–476.

10. Williams D. The structure of emotions reflected in epileptic experiences. Brain 1956;79:29–67.

11. Barczak P. Hypomania following complex partial seizures. Br J Psychiatry 1988;152:137–139.

12. Barry JJ, Lembke A, Huynh N. Affective disorders in epilepsy. In AB Ettinger, AM Kanner (eds), Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Philadelphia: Lippincott Williams & Wilkins, 2001;45–71.

13. Hypomania following complex partial seizures (letter). Br J Psychiatry 1988;152:571–572.

14. Byrne A. Hypomania following increased epileptic activity. Br J Psychiatry 1988;153:573–574.

15. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155(3):325–336.

16. Menza MA, Murray GB, Holmes VF, Rafuls WA. Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung 1988;17:238–241.

17. McConnell H, Duncan D. Treatment of psychiatric comorbidity in epilepsy. In H McConnell, PJ Snyder (eds), Psychiatric Comorbidity in Epilepsy: Basic Mechanisms, Diagnosis, and Treatment. Washington, DC: American Psychiatric Press, 1998;245–362.

18. Trimble MR, Ring HA, Schmitz B. neuropsychiatric aspects of epilepsy. In BS Fogel, RB Schiffer, SM Rao (eds), Neuropsychiatry. Baltimore: Williams & Wilkins, 1996.

19. Reynolds EH, Chanarin I, Milner G, Matthews DM. Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms. Epilepsia 1966;7:261–270.

20. Trimble MR, Corbett JA, Donaldson D. Folic acid and mental symptoms in children with epilepsy. J Neurol Neurosurg Psychiatry 1980;43:1030–1034.

21. Charney MN. Psychiatric aspects of folate deficiency. In MI Botez, EH Reynolds (eds), Folic Acid in Neurology, Psychiatry, and Internal Medicine. New York: Raven Press, 1979;475–482.

22. Froscher W, Maier V, Laage M, et al. Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Clin Neuropharmacol 1995;18:165–182.

23. Charney DS, Berman RM, Miller HL. Treatment of depression. In AF Schatzberg, CB Nemeroff (eds), Textbook of Psychopharmacology (2nd ed).Washington, DC: American Psychiatric Press, 1998;705–732.

24. Robertson MM, Trimble MR, Townsend DRA. Phenomenology of depression in epilepsy. Epilepsia 1987;28:364–372.

25. Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909–917.

26. Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. Pediatrics 1990;85:1086–1091.

27. Trimble MR. New antiepileptic drugs and psychopathology. Neuropsychobiology 1998;38:149–151.

28. Ring HA, Trimble MR. Depression in epilepsy. In SE Starkstein, RG Robertson (eds), Depression in Neurologic Disease. Baltimore: Johns Hopkins University Press, 1993.

29. Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, DC: American Psychiatric Press.

30. Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. J Clin Psychiatry 1997;58:3–11.

31. Yudofsky SC, Silver JM, Hales RE. Treatment of agitation and aggression. In SC Yudofsky, RE Hales (eds), The American Psychiatric Press Textbook of Neuropsychiatry. Washington, DC: American Psychiatric Press, 1997;881–900.

32. Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology (3rd ed). Washington, DC: American Psychiatric Press, 1997.

33. Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1982;33(5):646–648.

34. Ojemann LM, Baugh-Bookman C, Dudley DL. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 1987;37:1525–1527.

35. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Discord 1985;9:127–136.

36. Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995;45:1926–1927.

37. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289–299.

38. Labellarte MJ, Walkup JT, Riddle MA. The new antidepressants: selective serotonin reuptake inhibitors. Child Adolesc Psychopharmacol 1998;45(5):1137–1155.

39. Ryan ND, Varma D. Child and adolescent mood disorders—experience with serotonin-based therapies. Biol Psychiatry 1998;44:336–340.

40. McConville BJ, Chaney RO, Browne KL, et al. Newer antidepressants: beyond selective serotonin reuptake inhibitor antidepressants. J Child Adolesc Psychopharmacol 1998;45(5):1157–1171.

41. Cohn JB, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51:28–33.

42. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256–261.

43. Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988;49(7):262–266.

44. Jabbari B, Bryan GE, Marsh EE, Gunderson CH. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985;42:480–481.

45. Jick SS, Jick H, Knauss TA, et al. Antidepressants and convulsions. J Clin Psychopharmacol 1992;12:241–245.

46. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study in association with bupropion. J Clin Psychiatry 1991;52:450–456.

47. Leonard BE. Safety of amoxapine. Lancet 1989;2:808.

48. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450–477.

49. Montgomery SA. Novel selective serotonin reuptake inhibitors (part 1). J Clin Psychiatry 1992;53:107–112.

50. Peck AW, Sterm WC, Watkinson C. Incidence of seizures during treatment of tricyclic antidepressants and bupropion. J Clin Psychiatry 1983;44:197–201.

51. Tasini M. Complex partial seizures in a patient receiving trazodone. J Clin Psychiatry 1986;47:318–319.

52. Wedin GP, Oderda GM, Klein-Schwartz W, Gormun RL. Relative toxicity of cyclic antidepressants. Ann Emerg Med 1986;15:797–804.

53. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985;46:59–67.

54. Litovitz TL, Troutman WG. Amoxapine overdose. Seizures and fatalities. JAMA 1983;250(8):1069–1071.

55. Merigan KS, Browning RG, Leeper KV. Successful treatment for amoxepine-induced refractory status epilepticus with propofol. Acad Emerg Med 1995;2(2):128–133.

56. Dunner DL, Zisok S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59(7):366–373.

57. Phillips S, Brent J, Kulig K, et al. Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. J Emerg Med 1997;15(4):439–445.

58. Feeney DJ, Klykylo M. Medication-induced seizures. J Am Acad Child Adolesc Psychiatry 1997;36(8):1018–1019.

59. Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999;40[Suppl 10]:S71–S76.

60. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160–162.

61. Personne M, Persson H, Sjoberg G. Citalopram toxicity. Lancet 1997;350:519.

62. Setzer SC, Anderson DA, Lawler RJ, et al. Acute venlafaxine overdose—a multicenter study. J Toxicol Clin Toxicol 1995;33:496–497.

63. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors (part 1). J Clin Psychopharmacol 1996;16(4):273–285.

64. Nemeroff CB, DeVane CL, Pollock BG. New antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153(3):311–320.

65. Michalets EL. Update: clinically significant cytochrome P-450 drug interaction. Pharmacotherapy 1998;18(1):84–112.

66. Mullen WJ, North DS, Weiss MA. Pharmaceuticals and the cytochrome P450 isoenzymes: a tool for decision making. Pharm Pract News 1998;25:20–23.

67. Pham Z, Anderson PO. Cytochrome P450 in drug metabolism and interactions. Discourse 1996;18(1):1–4.

68. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15:84S–99S.

69. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31(3):198–214.

70. Droulers A, Bodak N, Oudjhani M, et al. Decrease of valproic acid concentration in the blood when coprescribed with fluoxetine. J Clin Psychopharmacol 1997;17:139.

71. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583–584.

72. Gernaat HBPE, van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry 1991;148:1604–1605.

73. Grimsley SR, Jann MW, Carter G, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10–15.

74. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997;17:107–109.

75. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992;55:412–413.

76. Lucena MI, Blanco E, Corrales MA, et al. Interaction of fluoxetine and valproic acid. Am J Psychiatry 1998;155:575.

77. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990;51:126.

78. Weber SW. Drug interactions with antidepressants. CNS [Special Ed] 1999;Spring:47–55.

79. Baldessarini RJ, Teicher MH, Cassidy JW, et al. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1998;8(5):381–382.

80. Nelson JC. Augmentation strategies with serotonin-noradrenergic combinations. J Clin Psychiatry 1998;59(S5):65–69.

81. Thompson GA. Serotonin syndrome. Drug Consults 1999, vol. 99. Micromedex, Inc.

82. Steinbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705–713.

83. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527–533.

84. Dursun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342:442–443.

85. Marder S. Antipsychotic medications. In AF Schatzberg, CB Nemeroff (eds), Textbook of Psychopharmacology (2nd ed). Washington, DC: American Psychiatric Press, 1998;309–322.

86. PCS Rx Reviews. Antipsychotics: emphasis on side effects. CNS Disorders–Schizophrenia 1998.

87. Owens MJ, Risch SC. Atypical antipsychotics. In AF Schatzberg, CB Nemeroff (eds), Textbook of Psychopharmacology (2nd ed).Washington, DC: American Psychiatric Press, 1998;323–348.

88. Lane HY, Chang WH, Chou JC. Seizure during risperidone treatment in an elderly woman treated with concomitant medications. J Clin Psychiatry 1998;59(2):81–82.

89. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58[Suppl 10]:55–62.

90. Wilson WH, Claussen AM. Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 1994;55(5):184–188.

91. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996;22(3):475–483.

92. Lee JW, Crismon ML, Dorson PG. Seizure associated with olanzapine. Ann Pharmacother 1999;33:554–556.

93. Denney D, Stevens JR. Clozapine and seizures. Biol Psychiatry 1995;37:425–426.

94. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:236–238.

95. Pacia SV, Devinsky O. Clozapine-related seizures. Neurology 1994;44:2247–2249.

96. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992;63:51–70.

97. Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991;9(1):37–51.

98. Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987;9:135–141.

99. Cold JA, Wells BG, Froemming JH. Seizure activity associated with antipsychotic therapy. DICP 1990;24:601–606.

100. McDougle J, Holmes JP, Carlton DC, et al. Double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633–641.

101. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997;27(3):313–323.

102. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1996;32(4):721–729.

103. Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19(1):37–44.

104. Ninan TN, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. In AF Schatzberg, CB Nemeroff (eds), Textbook of Psychopharmacology (2nd ed). Washington, DC: American Psychiatric Press, 1998;287–300.

105. Peroutka SJ, Gonzales DA, Shapiro M. Modulation of postdecapitation convulsions in rats by alpha-adrenergic and 5-hydroxytryptamine 1A agents. Exp Neurol 1987;96(2):344–351.

106. Catalano G, Catalano MC, Hanley PF. Seizures associated with buspirone overdose: case report and literature review. Clin Neuropharmacol 1998;21(6):347–350.

107. Goldberg RS, Posner DA. Anxiety in the medically ill. In A Stoudemire, B Fogel (eds), Psychiatric Care of the Medical Patient. New York: Oxford University Press, 1993;87–104.

108. Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol 1996;34(3):273–278.

109. Raju SS, Gopalakrishna HN, Venkatadri N. Effect of propranolol and nifedipine on maximal electroshock-induced seizures in mice: individual and in combination. Pharmacol Res 1998;38(6):449–452.

110. Akkan AG, Yillar DO, Eskazan E, et al. The effect of propranolol on maximal electroshock seizures in mice. Int J Clin Pharmacol Ther Toxicol 1989;27(5):255–257.

111. Muller M, Schramek J. Combined application of propranolol and local anesthetics: enhanced anticonvulsant action. Biomed Biochim Acta 1989;48(4):333–336.

112. Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective? J Pediatr 1997;130:670–674.

113. Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992;53(3):86–89.

114. Shukla S, Mukherjee S, Decina P. Lithium in the treatment of bipolar disorders associated with epilepsy: an open study. J Clin Psychopharmacol 1988;8(3):201–204.

Adapted from: Barry JJ and Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;205–217. With permission from Elsevier (www.elsevier.com).

Authored By: 
John J. Barry MD
Nga Huynh PharmD
Reviewed By: 
Steven C. Schachter MD
Tuesday, June 1, 2004